Clinical trial · Observational
Biology and Genetics of Smouldering Myeloma
Characterising Risk and Biology Of Smouldering Myeloma for Early Detection Of Symptomatic Myeloma
NCT05047107CI-TRIAL-00053911COSMOSunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational clinical trial recruiting Smouldering Myeloma patients (SMM) or potential SMM patients. Study involves collecting blood and bone marrow samples to determine the features of the tumour genome and BM microenvironment, including immune dysfunction that are key drivers of progression from precursor conditions (MGUS and SMM) to MM.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| MGUS | Monoclonal Gammopathy of Undetermined Significance | ALIAS | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Smouldering Myeloma | Smoldering Multiple Myeloma | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Genomic markers of progression
- timeFrame
- 5 years
- description
- To characterise genomic markers of progression by sequencing and studying the biology of bone marrow (BM) derived tumour cells.
Secondary outcomes (1)
- measure
- Immune biomarkers
- timeFrame
- 5 years
- description
- To define clonal heterogeneity and biomarkers of progression using liquid biopsies(blood), comparing with BM, and exploring the utility of serial samples.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Any individual with a confirmed or suspected diagnosis of MGUS, SMM, or MM. Exclusion Criteria: * Patients under the age of 18 * Patients with active symptomatic myeloma at diagnosis * Patients with no evidence of MGUS, sMM or MM * Patients with rapidly rising paraprotein or serum free light chains suggestive of progressive disease at time of diagnosis or inclusion into study
References
Publications (0)
Data not yet available
No reference posted for this study.